Camino de migas

Camino de migas

Estás en:

Publicador de contenidos

INFORME INAHTA

Informe completoLenvatinib and sorafenib for differentiated thyroid cancer after radioactive iodine: a systematic review and economic evaluation

Resumen: Lenvatinib and sorafenib for differentiated thyroid cancer

Objetivo: The remit of this research was to assess the clinical effectiveness and cost-effectiveness of lenvatinib and sorafenib within their European Union marketing authorisations for the treatment of patients with RR-DTC.

Autoría: NIHR Health Technology Assessment programme

Idioma: inglés

Fuente: INAHTA

Año de publicación: 2020